TORONTO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to support human wellness in innovative ways, is pleased to report that, further to its news release dated June 25, 2024, it has completed the sale today of the shares (the "Closing") of CannMart Inc. ("CannMart"), a B2B wholesale distribution business facilitating recreational cannabis sales ...

Core Viewpoint - LifeStance Health Group (LFST) shows potential for further upside, with a mean price target of $7.93 indicating a 26.7% increase from its current price of $6.26 [1] Price Target Analysis - The mean estimate consists of seven short-term price targets with a standard deviation of $1.43, indicating variability among analysts [2] - The lowest estimate is $6, suggesting a 4.2% decline, while the highest estimate is $10, indicating a potential surge of 59.7% [2] - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement [7] Earnings Estimates - Analysts have shown increasing optimism about LFST's earnings prospects, with a strong consensus in revising EPS estimates higher [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 3.9%, with two estimates moving higher and no negative revisions [10] - LFST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11]

TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF) My Fellow Shareholders, Further to my previous letter of August 15, 2024, we wish to remind you of the reasoning behind the strategic decision to divest Lifeist of CannMart Inc. ("CannMart") via a sale to Simply Solventless Concentrates Ltd. ("SSC") per our press release of June 25, 2024, and why shareholders should vote in favor of the transaction at the Annual and Special Meeting on September 5 ...

Core Insights - Lifeist Wellness Inc. is expanding its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. by partnering with impact.com to enhance its affiliate marketing strategy, which is crucial for growth in the nutraceutical industry [1][3][4] - The global partnership and affiliate marketing market was valued at $20.4 billion in 2022 and is projected to grow to $39.8 billion by 2031, indicating significant potential for revenue generation in this sector [3] Company Overview - Lifeist Wellness Inc. focuses on leveraging advancements in science and technology to create innovative ventures aimed at transforming human wellness, with Mikra specializing in cellular health products [5][7] - Mikra aims to utilize impact.com's tools to effectively manage and optimize partnerships, thereby driving sales growth and customer acquisition [3][4] Industry Context - The partnership and affiliate marketing sector is experiencing rapid growth, driven by the rise of social media and decentralized media platforms, which allow diverse voices to reach broader audiences [3] - impact.com is recognized as a leading partnership management platform, supporting over 225,000 active partnerships for major brands, which highlights the importance of strategic partnerships in customer acquisition [6]

Core Viewpoint - LifeStance Health Group (NASDAQ:LFST) is positioned for continued growth due to its strong value proposition in mental health care and the increasing prevalence of mental illness in the US [2][16]. Company Overview - LFST operates a health provider platform offering mental health care through a hybrid model of in-person and telehealth services, primarily in the United States [3]. - In Q2 2024, LFST reported total revenue of $312 million, exceeding consensus expectations and reflecting a 20.3% year-over-year growth, driven by a 5% increase in revenue per clinician [3]. - The company expanded its clinician base by 14% in the quarter, totaling 6,984 clinicians [3]. - Adjusted EBITDA for Q2 2024 was $28.6 million, significantly above consensus estimates and management guidance, with an adjusted EBITDA margin of 9.2%, up 370 basis points year-over-year [3][10]. - Management raised FY24 revenue guidance to $1.20–$1.242 billion and adjusted EBITDA guidance to $90–$100 million, with positive free cash flow expected for the full year [3]. Growth Potential - LFST's hybrid model enhances accessibility for patients, reducing time and psychological barriers associated with seeking mental health care [4][5]. - The model allows LFST to reach a wider geographical area and capture untapped patient demand, leading to increased utilization of clinician services [6]. - The prevalence of mental illness in the US is significant, with over 1 in 5 adults affected, indicating a growing market for LFST's services [7]. Profit Margin Trends - LFST has shown improvement in its adjusted EBITDA margin, which is expected to reach double digits by FY25, supported by operational efficiencies and increased revenue [9][10]. - Despite a projected decrease in margin for Q3 2024, this is attributed to seasonal trends and proactive investments by management to enhance future performance [10]. Valuation Insights - LFST is projected to achieve approximately $1.4 billion in revenue by FY25, with an adjusted EBITDA margin of around 10% [13]. - The company is valued at a forward EBITDA multiple of 21x, which is considered attractive compared to peers, particularly given its higher profitability [12][14].

TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to announce that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. ("Mikra") invites customers to sign up for VIP Early Access to the FOCUS Pre-Sale at https://wearemikra.com/pages/focus-signup-page. Mikra's n ...

TORONTO, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to report that it has completed, pursuant to a share purchase agreement entered into on August 16, 2024 with an arm's length party, the acquisition of the shares of 1000594871 Ontario Corp. ("4871") which holds key intell ...

LifeStance Health Group (LFST) closed the last trading session at $5.84, gaining 3.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $8.14 indicates a 39.4% upside potential. The average comprises seven short-term price targets ranging from a low of $6 to a high of $10, with a standard deviation of $1.46. While the lowest estimate indicates an increase of 2.7% from the current pri ...

Group 1 - LifeStance Health Group (LFST) shares have increased by 13.7% over the past four weeks, closing at $5.58, with a mean price target of $8.64 indicating a potential upside of 54.8% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $0.94, where the lowest estimate suggests a 25.5% increase and the highest predicts a 79.2% surge to $10 [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as indicated by a 3.8% increase in the Zacks Consensus Estimate for the current year [10][11] Group 2 - The Zacks Rank for LFST is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a solid potential upside [12] - While price targets are often viewed skeptically due to their misleading nature, a tight clustering of targets indicates a high degree of agreement among analysts regarding the stock's price movement [8][9] - Analysts' optimistic price targets may be influenced by business relationships, leading to inflated estimates, which investors should consider when making decisions [7]

Core Insights - Lifeist Wellness Inc. is launching a new product called FOCUS, developed by its U.S. biosciences subsidiary Mikra Cellular Sciences Inc., in collaboration with former MLB player Jose Bautista [2][12] - FOCUS is designed to enhance memory, concentration, and cognition using a blend of citicoline, tyrosine, and lion's mane mushroom, without caffeine or stimulants [2][4][6] - The product is set to be launched in late September 2024, with a comprehensive marketing plan in place [2][12] Company Overview - Lifeist Wellness Inc. focuses on health-tech innovations that transform human wellness through scientific advancements [2][18] - The company operates multiple business units, including Mikra, which specializes in biosciences and consumer wellness products, and CannMart, which deals with cannabis distribution [18] Product Development - The development of FOCUS involved extensive third-party clinical research to determine the optimal formula for cognitive enhancement [2][6] - The active ingredients in FOCUS have been clinically studied and shown to support improved cognitive functions [6][13] Market Strategy - The marketing plan for FOCUS is being developed with insights and resources provided by Jose Bautista, emphasizing the importance of market research and strategic planning [3][12] - Lifeist aims to reach a broader customer base in 2024 and beyond, leveraging the growing nutraceutical market, which is expected to remain a multi-billion dollar industry [16][18]